Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

被引：1

作者：

Tannir, N. ^{[1
]}

Powles, T. ^{[2
]}

Motzer, R. J. ^{[3
]}

Rolland, F. ^{[4
]}

Gravis, G. ^{[5
]}

Staehler, M. ^{[6
]}

Rink, M. ^{[7
]}

Retz, M. ^{[8
]}

Csoszi, T. ^{[9
]}

McCaffrey, J. ^{[10
]}

De Giorgi, U. ^{[11
]}

Caserta, C. ^{[12
]}

Cheporov, S. ^{[13
]}

Esteban Gonzalez, E. ^{[14
]}

Duran, I. ^{[15
]}

Larkin, J. G. ^{[16
]}

Berg, W. ^{[17
]}

Clary, D. ^{[17
]}

Escudier, B. ^{[18
]}

Choueiri, T. K. ^{[19
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA

[2] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med, London, England

[3] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[4] ICO Inst Cancerol Ouest Rene Gauducheau, Med Oncol, St Herblain, France

[5] Inst Paoli Calmettes, Med Outpatient, Urol, Marseille, France

[6] Maximilians Univ Munchen, Klinikum Ludwig, Urol, Munich, Germany

[7] Univ Med Ctr Hamburg Eppendorf, Urol, Hamburg, Germany

[8] Klinikum Rechts Isar Tech, Urol, Munich, Germany

[9] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Med Oncol & Hematol, Szolnok, Hungary

[10] Mater Private Hosp, Med Oncol, Oncol, Dublin, Ireland

[11] Ist Sci Romagnolo Studio & Cura Tumori, Med Oncol, Meldola, Italy

[12] Azienda Osped Sta Maria, Oncol, Terni, Italy

[13] Reg Clin Oncol Hosp, Clin Oncol, Yaroslavl, Russia

[14] Clinica, Oncol, Edificio Consultas Externas, Oviedo, Spain

[15] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain

[16] Royal Marsden Hosp NHS Fdn Trust, Med Oncol, London, England

[17] Exelixis Inc, Med Affairs, San Francisco, CA USA

[18] Inst Gustave Roussy, Immunotherapy & Innovat Therapy Unit, Villejuif, France

[19] Brigham & Womens Hosp, Dana Farber Canc Inst, Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw373.45

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

818P

引用

页数：1

共 50 条

[31] Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study
Escudier, Bernard J.
Powles, Thomas
Motzer, Robert J.
Olencki, Thomas
Aren, Osvaldo Rudy
Oudard, Stephane
Bracarda, Sergio
Tomczak, Piotr
Castellano, Daniel E.
Appleman, Leonard Joseph
Drabkin, Harry A.
Vaena, Daniel A.
Milwee, Steven
Youkstetter, Jillian
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[32] Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
Schmidinger, Manuela
Motzer, Robert J.
Rolland, Frederic
Straehler, Michael
Rink, Michael
Retz, Margitta
Csoszi, Tibor
McCaffrey, John A.
De Giorgi, Ugo
Caserta, Claudia
Duran, Ignacio
Benzaghou, Fawzi
Clary, Douglas O.
Albiges, Laurence
Choueiri, Toni K.
Tannir, Nizar M.
ACTA ONCOLOGICA, 2022, 61 (01) : 52 - 57
[33] CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
Sharma, P.
Escudier, B.
McDermott, D. F.
George, S.
Hammers, H. J.
Srinivas, S.
Tykodi, S. S.
Sosman, J. A.
Procopio, G.
Plimack, E. R.
Castellano, D.
Gurney, H.
Donskov, F.
Bono, P.
Wagstaff, J.
Gauler, T. C.
Ueda, T.
Xu, L. A.
Waxman, I. M.
Motzer, R. J.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S708
[34] Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
Thomas Powles
Toni K. Choueiri
Robert J. Motzer
Eric Jonasch
Sumanta Pal
Nizar M. Tannir
Sabina Signoretti
Rajesh Kaldate
Christian Scheffold
Evelyn Wang
Dana T. Aftab
Bernard Escudier
Daniel J. George
BMC Cancer, 21
[35] Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study
Grande, E.
Choueiri, T. K.
Motzer, R. J.
Escudier, B.
Pal, S.
Kollmannsberger, C.
Pikiel, J.
Gurney, H.
Rha, S. Y.
Park, S. H.
Geertsen, P. F.
Goupil, M. Gross
Suarez, C.
Arroyo, A.
Dean, M.
George, D.
Powles, T.
EUROPEAN JOURNAL OF CANCER, 2017, 72 : S197 - S198
[36] A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
Choueiri, T. K.
Escudier, B.
Powles, T.
Cella, D.
Lee, Y.
Laird, D. A.
Scheffold, C.
Motzer, R. J.
BJU INTERNATIONAL, 2013, 112 : 4 - 4
[37] Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
Cella, David
Escudier, Bernard
Tannir, Nizar M.
Powles, Thomas
Donskov, Frede
Peltola, Katriina
Schmidinger, Manuela
Heng, Daniel Y. C.
Mainwaring, Paul N.
Hammers, Hans J.
Lee, Jae Lyun
Roth, Bruce J.
Marteau, Florence
Williams, Paul
Baer, John
Mangeshkar, Milan
Scheffold, Christian
Hutson, Thomas E.
Pal, Sumanta
Motzer, Robert J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 757 - +
[38] Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo
Qin, Qian
Brugarolas, James
Hammers, Hans J.
Arafat, Waddah
Courtney, Kevin Dale
Wang, Jue
Jiang, Changchuan
Zhang, Song
Cowey, Charles Lance
Hutson, Thomas E.
Zhang, Tian
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
Grassi, Paolo
Verzoni, Elena
Mennitto, Alessia
Procopio, Giuseppe
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2016, 5 (06) : 974 - 976
[40] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (vol 21, 904, 2021)
Powles, Thomas
Choueiri, Toni K.
Motzer, Robert J.
Jonasch, Eric
Pal, Sumanta
Tannir, Nizar M.
Signoretti, Sabina
Kaldate, Rajesh
Scheffold, Christian
Wang, Evelyn
Aftab, Dana T.
Escudier, Bernard
George, Daniel J.
BMC CANCER, 2021, 21 (01)

← 1 2 3 4 5 →